Stocktoria
Neuraxis, INC NRXS
NYSE American · XASE · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2023-08-09
Neuraxis, INC financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $3.6M | $2.7M | $2.5M | $2.7M |
| Gross profit | $3.0M | $2.3M | $2.2M | $2.4M |
| R&D expense | $493,611 | $433,614 | $169,315 | $225,610 |
| Operating income | -$7.8M | -$7.2M | -$6.7M | -$3.4M |
| Interest expense | $73,969 | $174,328 | $476,416 | $318,666 |
| Net income | -$7.8M | -$8.2M | -$14.6M | -$4.8M |
| EPS (diluted) | $-0.95 | $-1.22 | $-4.50 | $-2.77 |
| Operating cash flow | -$6.4M | -$6.1M | -$6.7M | -$2.3M |
| Free cash flow | -$6.5M | -$6.1M | -$6.7M | -$2.3M |
| Cash & equivalents | $5.0M | $3.7M | $78,560 | $253,699 |
| Inventory | $257,132 | $44,328 | $21,220 | $48,133 |
| Total assets | $6.4M | $4.8M | $509,498 | $1.5M |
| Total liabilities | $3.0M | $2.7M | $1.9M | $7.1M |
| Shareholders' equity | $3.4M | $2.1M | -$1.4M | -$5.6M |
Growth · year-over-year · Revenue CAGR 10%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +32.9% | +9.2% | -8.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001933567 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.